Published guidance, NICE advice and quality standards

Showing 31 to 40 of 752

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Risdiplam for treating spinal muscular atrophy	TA755	16 December 2021	15 December 2023
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	TA939	13 December 2023	13 December 2023
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)	TA938	7 December 2023	7 December 2023
Secukinumab for treating moderate to severe hidradenitis suppurativa	TA935	6 December 2023	6 December 2023
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)	TA936	30 November 2023	30 November 2023
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)	TA933	29 November 2023	29 November 2023
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms	TA934	29 November 2023	29 November 2023
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)	TA932	23 November 2023	23 November 2023
Zanubrutinib for treating chronic lymphocytic leukaemia	TA931	22 November 2023	22 November 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments	TA930	15 November 2023	15 November 2023